Semaglutide

How It Works

The biology, explained.

Your body has a built-in communication system that helps coordinate hunger, digestion, and blood sugar.

One of its messengers is a hormone called GLP-1.

Semaglutide acts like this hormone, but stays active much longer.

Three important effects

Less hunger

Semaglutide affects appetite-related signals in the brain. Many people feel satisfied with smaller meals and experience fewer cravings.

Better blood sugar control

It helps the pancreas release insulin when blood sugar is elevated and reduces inappropriate glucagon release. Together, these effects improve blood sugar regulation.

Slower digestion

Semaglutide delays stomach emptying, especially early in treatment. This can contribute to fullness, but it also helps explain some digestive side effects.

What about "food noise"?

This is one of the most interesting things people describe.

Food noise refers to persistent thoughts about eating—the cravings, planning, and mental chatter surrounding food.

Some people say semaglutide makes those thoughts dramatically quieter.

Imagine walking past your favorite snack and realizing you genuinely don't care whether you eat it.

For some people, that's a surprisingly big change.

Go deeper: The science

Semaglutide is a GLP-1 receptor agonist.

It activates the GLP-1 receptor, which influences insulin secretion, glucagon regulation, appetite, and gastrointestinal function.

A modification to its molecular structure allows it to remain active longer than natural GLP-1.

Its elimination half-life is approximately one week.

Unlike tirzepatide, which activates both GIP and GLP-1 receptors, semaglutide targets the GLP-1 receptor.

The Evidence

What do the studies actually show?

Semaglutide is one of the more extensively researched medications in modern metabolic medicine.

And the evidence covers more than weight loss.

Weight loss: STEP 1

In a major trial involving 1,961 adults with obesity or overweight and a related health condition, but without diabetes, researchers compared weekly injectable semaglutide with placebo.

After 68 weeks:

Both groups received lifestyle counseling.

For perspective, a 15% reduction would equal 30 pounds for someone starting at 200 pounds.

That's an example, not a prediction for every person.

Heart protection: SELECT

This is where things get especially interesting.

Researchers studied more than 17,000 adults with existing cardiovascular disease and overweight or obesity, but without diabetes.

Over an average follow-up of about 40 months, major cardiovascular events occurred in:

• 6.5% of participants receiving semaglutide.
• 8.0% receiving placebo.

That represents approximately a 20% relative reduction in risk.

In other words, semaglutide demonstrated benefits beyond simply helping people lose weight.

Kidney protection: FLOW

Researchers also studied semaglutide in people with type 2 diabetes and chronic kidney disease.

The FLOW trial enrolled 3,533 participants.

Semaglutide reduced the risk of a combined outcome involving major kidney deterioration, kidney failure, or death from kidney-related or cardiovascular causes by approximately 24% relative to placebo.

These findings supported an additional approved indication for Ozempic.

Liver disease: ESSENCE

Semaglutide has also shown benefits in a form of fatty liver disease called MASH, where inflammation can lead to liver scarring.

In a phase 3 trial, researchers studied people with MASH and moderate-to-advanced fibrosis.

At 72 weeks, resolution of liver inflammation without worsening scarring occurred in:

• 62.9% of the semaglutide group.
• 34.3% of the placebo group.

The results supported accelerated FDA approval of Wegovy injection for certain adults with noncirrhotic MASH and liver fibrosis.

This is a specific medical indication, not proof that semaglutide treats every type of liver disease.

Compared with tirzepatide

In the SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide at the studied doses.

At 72 weeks:

• Tirzepatide: 20.2% average weight loss.
• Semaglutide: 13.7% average weight loss.

That doesn't make semaglutide ineffective or mean tirzepatide is automatically the right choice for everyone.

The two medications have different pharmacology, indications, tolerability considerations, and individual responses.

What happens after stopping?

Research shows that people can regain substantial weight after discontinuing semaglutide.

That doesn't mean the treatment failed.

It highlights the ongoing biological and behavioral challenges of managing obesity.

The takeaway: Semaglutide has strong clinical evidence for several important medical uses. Maintaining its benefits over time remains a major part of treatment.

Risks & Effects

What should people know?

Semaglutide has been studied in thousands of people, so its safety profile is much better understood than that of most investigational peptides.

But it's still a medication with important risks.

Common side effects

Nausea

One of the most frequently reported problems, particularly when beginning treatment or changing doses.

Constipation and diarrhea

Changes in bowel habits are common and sometimes frustrating.

Vomiting and abdominal discomfort

Some people experience significant digestive symptoms or find certain foods harder to tolerate.

Reflux and uncomfortable fullness

Slower stomach emptying can contribute to bloating, belching, reflux, and feeling full for longer than expected.

Important medical warnings

Thyroid tumor warning

Semaglutide caused thyroid C-cell tumors in rodents. Whether it causes these tumors in humans is unknown.

It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis and gallbladder disease

Pancreatitis has been reported with GLP-1 receptor medications, and gallbladder problems can occur.

Severe or persistent abdominal pain requires prompt medical evaluation.

Dehydration and kidney injury

Significant vomiting or diarrhea can lead to dehydration and kidney complications.

Diabetic eye disease

Worsening diabetic retinopathy has been observed in some patients, particularly in the setting of rapid improvement in blood sugar.

Low blood sugar

Hypoglycemia is an especially important concern when semaglutide is used with insulin or certain other diabetes medications.

Anesthesia and sedation

Delayed stomach emptying can increase the risk of retained stomach contents during anesthesia or deep sedation. Patients should tell their medical team that they use semaglutide.

Pregnancy

Semaglutide is not recommended for weight reduction during pregnancy. Product labeling advises stopping it at least two months before a planned pregnancy.

Different products, different instructions

Ozempic, Wegovy, and Rybelsus contain semaglutide, but they don't all have the same approved uses, formulations, or instructions.

Wegovy is available in injectable and oral forms, while Ozempic has its own approved indications.

A research vial labeled semaglutide isn't automatically equivalent to an FDA-approved prescription product.

Bottom line: Semaglutide has meaningful, well-established benefits, but the risks and product differences matter.

Real Experiences

What are people saying?

Semaglutide has generated an enormous amount of conversation in weight-loss and diabetes communities.

Some experiences line up closely with the clinical research. Others reveal how personal the treatment experience can be.

The good

One of the most frequently discussed experiences is quieter food noise.

Some people describe feeling satisfied after smaller meals, losing interest in constant snacking, or finally feeling less preoccupied with food.

Others talk about gradual, sustained weight loss and improved confidence.

For some, the biggest change isn't the number on the scale. It's feeling like food no longer occupies so much mental space.

The not-so-good

Digestive problems are a recurring theme in public discussions.

People describe nausea, constipation, reflux, fatigue, and struggling with meals they previously enjoyed.

Some find the symptoms manageable. Others describe them as disruptive enough to reconsider treatment.

The frustrating

Not everyone experiences dramatic appetite suppression.

Some people report little noticeable change at first. Others lose weight slowly, encounter plateaus, or find that hunger returns.

There are also accounts of weight regain after treatment stops.

The unexpected

Some people describe changes in their relationship with food that feel emotionally complicated.

Eating can be a source of pleasure, comfort, celebration, or social connection. When the desire to eat changes, that adjustment isn't always straightforward.

Others say they still enjoy food just as much—they simply feel satisfied sooner.

So what should we believe?

Clinical trials establish that semaglutide can improve several meaningful health outcomes.

Real experiences remind us that two people taking the same medication can have very different experiences.

The research gives us the averages. The stories remind us that people aren't averages.

These themes reflect real public discussions. Individual reports are unverified and do not establish how frequently an effect occurs or whether semaglutide caused it.